Vistagen's Social Anxiety Disorder Drug Disappoints In Pivotal Late-Stage Study

Vistagen Inc. (NASDAQ:VTGN) stock is plunging on Wednesday, with a session volume of 20.91 million compared to the average volume of 711,000, as per data from Benzinga Pro.The clinical-stage biopharmaceutical company focused on neuroscience announced that the PALISADE-3 Phase 3 study of intranasal fasedienol for the acute treatment of social anxiety disorder did not achieve its primary endpoint.PALISADE-3 public speaking challenge study was designed to evaluate the efficacy and safety of a single dose of fa ...